{"DataElement":{"publicId":"4449931","version":"1","preferredName":"Patient Neoplasm Personal Medical History Code Indicator","preferredDefinition":"The yes/no/not applicable response related to a person who receives medical attention, care, or treatment with history of an abnormal tissue growth resulted from uncontrolled cell proliferation.","longName":"PT_NEO_PMEDHX_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2957976","version":"1","preferredName":"Patient Neoplasm Personal Medical History","preferredDefinition":"information related to a person who receives medical attention, care, or treatment with history of an abnormal tissue growth resulted from uncontrolled cell proliferation.","longName":"2233604v1.0:2957974v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2957974","version":"1","preferredName":"Neoplasm Personal Medical History","preferredDefinition":"(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.:an account of all medical events and problems a person has experienced.","longName":"C3262:C18772","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Personal Medical History","conceptCode":"C18772","definition":"A record of a patient's background regarding health and the occurrence of disease events of the individual. In addition, personal medical history may be a variable in epidemiologic studies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7790ED63-7018-341E-E040-BB89AD435893","latestVersionIndicator":"Yes","beginDate":"2009-11-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-11-04","modifiedBy":"ONEDATA","dateModified":"2009-11-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7790ED63-7029-341E-E040-BB89AD435893","latestVersionIndicator":"Yes","beginDate":"2009-11-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-11-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000703","version":"1","longName":"Disease Status & Genetics","context":"Theradex"},{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has the patient had another malignancy within 5 years of study enrollment?","url":null,"context":"Theradex"},{"name":"Does patient have a history o","type":"Preferred Question Text","description":"Does patient have a history of another malignancy?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have a history of another malignancy? Except for patients who have been disease-free for 3 years, or patients with a history of completely resected non melanoma skin cancer and/or patients with indolent secondary malignancies, are eligible.","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"If normal and mild cohort: Does patient have prostate cancer, renal cell cancer, neuroendocrine tumor, lung cancer, colorectal cancer, soft tissue sarcoma, glioma or thyroid cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has a known additional malignancy that is progressing or requires active treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have a history of another primary malignancy, with the exception of: non-melanoma skin cancer, and carcinoma in situ of cervix, uteri or breast from which the patient has been disease free for greater than 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient have history of another malignancy other than the study indication under this trial within 5 years of study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Is there evidence of another malignancy which required systemic treatment within 2 years of the start of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Does patient have a history of another prior malignancy except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Does patient have another known active cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Does patient have a history of another primary malignancy, with the exception of: non-melanoma skin cancer, and carcinoma in situ of cervix, uteri or breast from which the patient has been disease free for greater than 3 years?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient had another active malignancy less than or equal to 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have active malignancies other than NSCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient been diagnosed with or received treatment for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have other active invasive malignancies?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"If patient has NSCLC does patient have metastatic or locally advanced disease that has progressed after at least one prior therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient have any other prior malignancy from which the patient has been disease free for less than 3 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Does patient have a history of another primary malignancy, with the exception of: non-melanoma skin cancer, and carcinoma in situ of cervix, uteri or breast from which the patient has been disease free for greater than 3 years?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient have a history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least three years?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Does patient have a history of prior malignancy, except as noted in section 3.2.12 of the protocol?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient had another malignancy other than the cervical cancer within 5 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the breast?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient have concomitant or prior invasive malignancies within the past 3 years?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does patient have a history of acute myeloid leukemia (AM), or a history of any other primary malignancy within 3 years prior to initiation of treatment on this study?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Has patient received treatment for a different cancer previously and has been disease free for less than 1 year?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient have known concurrent malignancy that is progressing or requires active treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient have a history of acute myeloid leukemia (AML), or a history of any other primary malignancy within 3 years prior to initiation of treatment on this study?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient have a concurrent, active malignancy in addition to that being studied (other than cutaneous squamous cell carcinoma or basal cell carcinoma)?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient have known active cancers and is on therapy for those cancers at time of screening?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient have a history of another primary malignancy, except for malignancy treated with curative intent and with no known active disease greater than or equal to 5 years before the first dose of study drug and of low potential risk for recurrence, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease or adequately treated carcinoma in situ without evidence of disease (eg, cervical cancer in situ)?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Does patient have any concomitant or prior invasive malignancy except for: Treated limited-stage basal cell or squamous cell carcinoma of the skin; Carcinoma in situ of the breast or cervix; Primary endometrial cancer meeting the following conditions: Stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO grade 3 lesions; Prior cancer treated with curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"If patient is enrolled in Phase II: Does patient have active malignancies other than SCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"If patient has a prior history of malignancy, have they been free of disease for greater than 3 years?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient have a known additional malignancy that is progressing or requires active treatment, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient have active malignancies other than SCLC or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient have a known additional malignancy that is progressing or requires active treatment, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Did the patient have second primary malignancy that would affect the safety of the treatment or the subject's ability to complete study-related procedures?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient have other active malignancy less than or equal to 3 years prior to registration for which active treatment is required?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If patient has a prior history of malignancy, have they been free of disease for greater than or equal to 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient have another uncontrolled malignancy?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient have concomitant or prior invasive malignancies within the past 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does patient have a history of another malignancy other than the study indication under this trial within 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient have a known additional malignancy that is progressing or requires active treatment, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy, the other cancer is in clinical remission for at least 2 years prior to Cycle 1 Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient have any concomitant or prior invasive malignancy except for: Treated limited-stage basal cell or squamous cell carcinoma of the skin; Carcinoma in situ of the breast or cervix; Prior cancer treated with curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient have a known concurrent malignancy that is expected to require active treatment within two years, or may interfere with the interpretation of the efficacy and safety outcomes of this study in the opinion of the treating investigator?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Does patient have known additional malignancy that is progressing or requires active treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient have concomitant or prior invasive malignancies within the past 5 years? ","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Does patient have a history of a different malignancy except for: 1) individuals with a history of other malignancies who have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, or 2) individuals with the following cancers if diagnosed and treated within the past 5 years: superficial bladder cancer, basal cell or squamous cell carcinoma of the skin?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does patient have a history of another malignancy within the past 5 years, except for: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for greater than or equal to 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Is patient known to have additional malignancies other than UBC within 2 years prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Does patient have other active cancers, or history of treatment for invasive cancer, within the last 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Is patient known to have additional malignancies other than UBC within 2 years before initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Does patient have a currently active second malignancy, other than non-melanoma skin cancers?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Does patient have other malignancy within the last 5 years except for: (a) adequately treated non-melanoma skin cancer (b) curatively treated in situ cancer of the cervix (c) ductal carcinoma in situ (DCIS) (d) Stage 1, grade 1 endometrial carcinoma or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for greater than or equal to 5 years?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Has patient had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does patient have a history of another active malignancy that limits survival to less than 1 year?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does patient have a history of other malignancy within 36 months prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Does patient have a concomitant second malignancy (except adequately treated SCC or BCC skin cancers or in situ bladder, breast or cervical cancers) within the last 3 years prior to study entry?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Does patient have active malignancies, other than NSCLC,  or prior curatively treated malignancy at high risk of relapse during the study period with the exception of localized squamous or basal cell skin cancers, ductal carcinoma in-situ (DCIS), or indolent cancer currently on observation (i.e. CLL or low-risk prostate cancer)?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Does patient have a previous or concurrent history of malignancies within 5 years prior to study treatments except for curatively treated: Cervical carcinoma in situ, Non-melanoma skin cancer, superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]), or localized prostate cancer?","url":null,"context":"Theradex"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"Did the patients have any other invasive malignancy within 5 years before randomization?","url":null,"context":"NRG"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Has patient had another malignancy within the last 5 years (except for: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumors including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for greater than or equal to 5 years)?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Does patient have a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Does patient have a history of active malignancies other than MM within the last 2 years unless treated with curative intent and has no evidence of active disease?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Does the patient have another malignancy, except if curatively treated with no evidence of disease for greater than or equal to 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), or stage 1 grade 1 endometrial carcinoma?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Does patient have a known additional malignancy that is progressing or requires active treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Does patient have a prior or concurrent malignancy, excluding non-melanoma skin cancers and non-invasive cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"If patient has a prior or concurrent malignancy, the natural history or treatment of that malignancy does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"Does patient have history of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years?","url":null,"context":"Theradex"},{"name":"NRG_CRF TEXT 1","type":"Alternate Question Text","description":"Does the patient have an underlying or documented history of hematologic malignancy (e.g., CLL)?","url":null,"context":"NRG"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Does patient have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does patient have a known additional malignancy that is progressing or requires active treatment, except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or insitu cervical cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Does patient have a history of malignancy within 3 years of the screening visit?  ","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"If patient has a prior or concurrent malignancy, the natural history or treatment of that malignancy does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the enrolling physician)?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"Does patient have a history of prior invasive rectal malignancy, regardless of disease-free interval?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"Does patient have a history of prior malignancies within the past 3 years other than non-melanomatous skin cancers that have been controlled?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"Does patient have a history of a clinically relevant second primary malignancy within the past 2 years?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Has the patient had multiple primary malignancies within 2 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Has the patient had multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, and other solid tumors curatively treated?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"Does patient have a history of additional malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless untreated and stable or disease free for at least 3 years?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Does patient have a history of a different malignancy, except if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"Does patient have history of malignancy 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate greater than 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Has patient had another prior malignancy, except for In situ cervical cancer or adequately treated basal cell or squamous cell skin cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, and any other cancer from which the patient has been disease-free for at least 1 year?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"If patient has a history of a prior malignancy, is patient receiving other specific treatment (other than hormonal therapy for their cancer)?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Does the participant have prior history of past or current other cancer, except for non-melanoma skin cancer or in situ cervical cancer within the past 5 years?","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008BF974-43B0-54F9-E050-BB89AD43385B","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"TSESU","dateModified":"2023-07-27","changeDescription":"9591_Theradex_08.13.14_ghd","administrativeNotes":"8/5/2022: fixed the box symbol in AQT_wz","unresolvedIssues":null,"deletedIndicator":"No"}}